Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PCSK9 inhibitors

- PMLiVE

Joint COVID-19 trial begins testing drugs from Amgen, UCB and Takeda

Trial will test therapeutic candidates in hospitalised COVID-19 patients

regeneron headquarters

Regeneron’s COVID-19 antibody cocktail scores FDA emergency approval

Drug approved to treat high-risk patients with mild to moderate COVID-19

Sanofi reception

Sanofi’s quadrivalent flu vaccine Supemtek scores EU approval

Company expects first EU launches in 2022/2023 flu season

- PMLiVE

AZ, Amgen’s investigational asthma drug comes good in phase 3

Tezepelumab evaluated in late-stage trial of severe asthma patients

- PMLiVE

Sanofi set to acquire Kiadis for €308m

Acquisition will see French pharma gain access to NK-cell platform

- PMLiVE

Regeneron halts enrolment of severely ill patients in COVID-19 antibody trial

Trial modified based on recommendations from independent data monitoring committee

Sanofi reception

Sanofi and Translate Bio eye launch of phase 1/2 COVID-19 vaccine study

Preclinical data for mRNA-based vaccine supports clinical development

- PMLiVE

Regeneron scores first FDA approval for Ebola antibody treatment

Treatment cut mortality rate in study based in the Democratic Republic of Congo

- PMLiVE

Regeneron seeks US emergency use authorisation for COVID-19 antibody cocktail

If approved, the US government will make initial doses available at no cost

- PMLiVE

Amgen, Cytokinetics’ heart failure drug disappoints in phase 3

Drug hit primary endpoint but missed secondary endpoint of reduction in cardiovascular death

- PMLiVE

Regeneron’s COVID-19 antibody cocktail reduces viral load and alleviates symptoms

Investigational treatment also helped patients recover faster

- PMLiVE

Sanofi, GSK to launch human trials of COVID-19 vaccine

Vaccine combines Sanofi’s baculovirus expression system and GSK’s AS03 adjuvant

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links